Early detection
Tumour-derived fragments may become detectable before symptoms emerge — identifying disease at earlier, more treatable stages.
Home / The Science
The science behind the testThree scientific shifts power our approach — liquid biopsy, cell-free DNA, and epigenetic methylation. Here is why each one matters.
For decades, tissue biopsy has been the gold standard for cancer diagnosis. While informative, it is invasive, costly, often painful, and frequently fails to capture the full biological complexity of a patient's disease.
Liquid biopsy is a paradigm shift. Rather than requiring surgical access to a tumour, it analyses tumour-derived biomarkers circulating in the bloodstream — cfDNA, ctDNA, RNA fragments, extracellular vesicles, and proteins — giving clinicians a dynamic molecular snapshot from a simple blood sample.
Every day, billions of cells undergo natural turnover, releasing fragmented DNA into the bloodstream — cell-free DNA (cfDNA). In cancer patients, a small fraction originates directly from tumour cells: circulating tumour DNA (ctDNA). Because ctDNA carries tumour-specific alterations, it lets us detect cancer without sampling the tumour itself.
Tumour-derived fragments may become detectable before symptoms emerge — identifying disease at earlier, more treatable stages.
After surgery or therapy, ctDNA can reveal microscopic residual disease undetectable by conventional imaging.
Changes in ctDNA levels give an early indication of therapeutic response — or of treatment failure.
Studies show ctDNA can identify molecular relapse months before radiological recurrence becomes apparent.
Unlike conventional tissue-based assays that depend on tumour biopsy specimens, we use highly sensitive cfDNA extraction and analysis to enable comprehensive molecular assessment from a simple blood draw. Our proprietary workflow is specifically optimized to preserve low-abundance DNA fragments — maximizing sensitivity in early-stage disease and low-tumour-burden settings where conventional approaches often fail.
Most platforms focus on genetic mutations. But mutations are only part of the story — long before visible tumours develop, cancer cells undergo profound epigenetic alterations that occur earlier, more consistently, and across more patients.
DNA methylation is a natural biochemical process in which methyl groups are added to specific DNA regions known as CpG islands. In healthy cells, methylation regulates normal gene expression.
In cancer cells, abnormal methylation patterns arise — inappropriately activating oncogenes and silencing tumour-suppressor genes. These aberrant signatures are among the earliest molecular events in cancer development, and they are often tissue-specific, enabling accurate identification of the tumour's origin.
We've developed a proprietary methylation-based platform designed for the molecular epidemiology of the Indian population, combining five technologies into one clinically actionable result.
We believe in continuous molecular surveillance that enables earlier intervention and more informed clinical decisions. Let's build it together.
Get in touch